ise-view-Article Detail Bottom List
Illumina, Annoroad to co-develop NGS reproductive health diagnostic system
Date Published：6/11/2015 11:06:10 PM
The collaboration, which signals the increasing importance of genomic applications to improve healthcare in China, will bring together technology from Illumina sequencers with advanced clinical application development capabilities from Annoroad
BEIJING and SAN DIEGO – Annoroad and Illumina, Inc. (NASDAQ: ILMN) have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The technology partnership will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market.
The collaboration, which signals the increasing importance of genomic applications to improve healthcare in China, will bring together technology from Illumina sequencers with advanced clinical application development capabilities from Annoroad.
“Illumina is very excited to collaborate with Annoroad to increase access to reproductive health solutions in China,” said Tristan Orpin, senior vice president and general manager of Illumina’s Reproductive and Genetic Health business. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.”
In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine, and in China, Annoroad was selected as the national clinical pilot site of NGS in China given its major position in the domestic market and next-gen sequencing technology.
“We have been working to promote the clinical application of genomic technology in China. Non-invasive prenatal testing is used widely in the reproductive health arena, and we hope to promote it as a standard practice in hospitals,” said Junbin Liang, Annoroad founder and chief executive officer. “Annoroad is now very pleased to partner with Illumina, the global leader in sequencing and array technologies. Cooperation between our two companies will provide additional high-quality diagnostic solutions in the field of reproductive health.”
As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.